Dear Reader,
Today I want to revisit my No. 1 takeover target…
Those of you who have been around for a while will remember, in 2018, 2019 the biotech industry got hammered.
And all of a sudden, these great companies that were creating incredibly novel, revolutionary treatments were seeing their stocks just get crushed.
Like Loxo Oncology, Tesaro, Array Biopharma …
I started to recommend them because they were just incredible bargains.
All these companies were making breakthroughs in cancer – obviously a huge market, sadly.
And as these good companies were, they were getting hammered so hard they just started getting taken over.
Big pharma, the “smart money” didn’t sit around – they were taking advantage of low prices!
Loxo was bought by Eli Lilly three days after we recommended it. We recommended it Friday, it was taken over Monday.
It was great!
Tesaro was bought out by Glaxo 63 days after we recommended it …
Array Biopharma was acquired by Pfizer shortly after we recommended it.
And we are in one of those similar times now in the biotech sector.
Even as the broader market has marched higher, biotech’s gotten hammered over the last six months!
Even as AI is revolutionizing this sector …
And even, especially biotechs that have new FDA-approved drugs on the market.
Especially ones that could treat a BIG market …
And especially ones focused on oncology, cancer.
I’ll tell you, when a situation like this arises, we get as excited as Big Pharma does.
It’s happening. And I’m pumped!
Right now, the stock we’re so excited about is a company that won FDA approval, and just got a major new vote of confidence for its flagship therapy…
It just published results of a full five-year analysis showing the kind of long-term results doctors (and investors) have been waiting for.
They’ve got the only drug for a certain type of solid tumor out there and they are just attacking the market.
And we believe that this company, which has had takeover talks already with other big pharma giants like Gilead …
Is a prime takeover target.
And we’re not the only ones who believe this.
Billionaire investors and insiders who specialize in biotech investing have been buying massive amounts of this stock.
That’s why this opportunity is so urgent.
Click here now to get, “Our No. 1 Takeover Target for July.”
This could be my no. 1 takeover target all year. The science here is incredible.
But my team will be taking this report offline sooner than later, so don’t miss it. Click here now before this comes offline.
My No. 1 takeover target is a really special opportunity I wanted to be sure we shared with you.
It’s not every day you have an industry bear market beating down a stock that’s dominating a big cancer market…
Showing double the survival rate of the leading drug in a long-term study…
And trading for under $5 a share.
This is as good as it gets when it comes to these takeover deals.
And our readers have done great with these – our win-rate is almost 100% on these deals for over 5 years running.
Click here now to see “Our No. 1 Takeover Target” report before it comes offline.
Tidak ada komentar:
Posting Komentar